Vaxcyte Inc Ordinary Shares PCVX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PCVX is a good fit for your portfolio.
News
-
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
-
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
-
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
-
Vaxcyte Announces Pricing of $750 Million Public Offering
-
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Trading Information
- Previous Close Price
- $60.72
- Day Range
- $60.72–62.29
- 52-Week Range
- $41.57–82.04
- Bid/Ask
- $58.11 / $69.88
- Market Cap
- $6.64 Bil
- Volume/Avg
- 500,655 / 787,079
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 254
- Website
- https://www.vaxcyte.com
Comparables
Valuation
|
Metric
|
PCVX
|
ICVX
|
HLVX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.64 | 3.30 | 2.26 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
PCVX
ICVX
HLVX
Financial Strength
|
Metric
|
PCVX
|
ICVX
|
HLVX
|
|---|---|---|---|
Quick Ratio | 7.43 | 17.59 | 10.37 |
Current Ratio | 7.54 | 18.06 | 10.62 |
Interest Coverage | — | — | −54.72 |
Quick Ratio
PCVX
ICVX
HLVX
Profitability
|
Metric
|
PCVX
|
ICVX
|
HLVX
|
|---|---|---|---|
Return on Assets (Normalized) | −21.69% | −29.30% | −34.03% |
Return on Equity (Normalized) | −23.31% | −31.87% | −42.52% |
Return on Invested Capital (Normalized) | −28.13% | −34.69% | −38.62% |
Return on Assets
PCVX
ICVX
HLVX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nbmxhzlfv | Jtjp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xctwfxqt | Ddvsm | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gfcqyjm | Kzxly | $97.3 Bil | |
MRNA
| Moderna Inc | Mjxlkjwd | Xrhg | $41.3 Bil | |
ARGX
| argenx SE ADR | Ccycvqsyv | Ycsj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mbphgfs | Xlzhs | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Txhpfttl | Trhtb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dmmbwwgf | Drgfjdd | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cxvzwsrq | Zqmykq | $12.6 Bil | |
INCY
| Incyte Corp | Bdwhsrnh | Vhwwch | $11.6 Bil |